AlphaQuest LLC Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

AlphaQuest LLC increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 136.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,231 shares of the company’s stock after acquiring an additional 5,913 shares during the period. AlphaQuest LLC’s holdings in Castle Biosciences were worth $273,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CSTL. Principal Financial Group Inc. lifted its position in Castle Biosciences by 2.7% in the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after purchasing an additional 40,377 shares during the last quarter. Bellevue Group AG increased its stake in shares of Castle Biosciences by 3.7% in the third quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock worth $35,993,000 after buying an additional 44,929 shares during the period. Portolan Capital Management LLC raised its holdings in Castle Biosciences by 3.7% during the 3rd quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock valued at $35,811,000 after buying an additional 44,676 shares during the last quarter. State Street Corp boosted its position in Castle Biosciences by 9.8% during the 3rd quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after buying an additional 60,924 shares during the period. Finally, Geode Capital Management LLC boosted its position in Castle Biosciences by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock valued at $17,820,000 after buying an additional 7,004 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Castle Biosciences

In related news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 2,130 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the sale, the insider now directly owns 78,335 shares in the company, valued at $1,529,099.20. The trade was a 2.65 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,568 shares of company stock valued at $1,321,364. Corporate insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on CSTL. Robert W. Baird upped their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences presently has an average rating of “Buy” and a consensus price target of $40.00.

Castle Biosciences Price Performance

CSTL stock opened at $19.29 on Friday. The firm has a 50-day moving average of $25.80 and a 200 day moving average of $28.63. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The company has a market cap of $540.26 million, a P/E ratio of 96.45 and a beta of 0.98. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.